PETMED EXPRESS INC
No financial data available for PETS.
Company may not file with SEC or CIK is unresolved.
PetMeds reported Q4 FY2026 revenue of $42.8M, down 15.6% YoY, with net loss of $0.19 per diluted share
“We are pleased to report a modest sequential quarterly increase in fourth quarter net sales, demonstrating positive momentum as we close out the year.”
No Form 4 transactions on record.
Informational purposes only, not investment advice.